18Nov 2022
Clinical efficacy of next-generation sequencing panels for hearing loss diagnostics.

Clinical efficacy of next-generation sequencing panels for hearing loss diagnostics.

Hearing loss (HL) is one of the most common disorders affecting the sensory system, characterized by high clinical and genetic heterogeneity with an estimated prevalence of 1–3 in every 1000 newborns and over 45 million individuals in the US.A total of 157 patients were included in this study with most patients having sensorineural hearing loss (n=113/157; 71.9%). The remaining had other indications for diagnostic testing including family history of disease, other disorders of aromatic amino-acid metabolism, intellectual disability, delayed speech, autism spectrum disorder; unspecified visual loss or dysmorphic features. These results illustrate the clinical efficacy of performing genetic testing for the indication of HL using our Sema4 comprehensive NGS panels that incorporate multiple laboratory methods.

  • #family health

Like

Save

Share